Physician profile
Jay Grochmal
NPI 1114914496
$691.52
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $302 · 2021: $135 · 2022: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $250.56 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $176.44 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $95.42 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $43.26 | 2022 | |
| Omeros Corporation | $38.58 | 2019-2021 | |
| Abbvie INC. | $35.41 | 2022 | |
| Oyster Point Pharma, INC. | $20.69 | 2022 | |
| Aerie Pharmaceuticals, INC. | $18.39 | 2019 | |
| Sight Sciences, INC. | $12.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Grochmal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.